ARTICLE | Clinical News
Mavoglurant regulatory update
December 3, 2012 8:00 AM UTC
The European Commission granted Orphan Drug designation to Novartis' mavoglurant to treat fragile X syndrome. The oral metabotropic glutamate receptor subtype 5 (mGluR5) antagonist is in Phase II/III...